Rapport Therapeutics (RAPP) Common Equity (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Common Equity data on file, last reported at $471.5 million in Q1 2026.

• On a quarterly basis, Common Equity rose 64.96% year-over-year to $471.5 million in Q1 2026; TTM through Mar 2026 was $471.5 million, a 64.96% increase from a year earlier, with the FY2025 full-year figure at $484.7 million, up 58.68% from the prior year.
• Common Equity for Q1 2026 stood at $471.5 million, down from $484.7 million in the prior quarter.
• Over the last five years, Common Equity for RAPP reached as high as $511.6 million in Q3 2025 and fell as low as -$39.6 million in Q1 2024.
• Historically, Common Equity has averaged $241.2 million across 4 years, with a median of $295.6 million in 2024.
• Across the five-year window, Common Equity soared 3671.36% in 2024 and declined 21.78% in 2025, its largest moves.
• Year by year, Common Equity stood at -$25.6 million in 2023, then surged by 1291.49% to $305.4 million in 2024, then surged by 58.68% to $484.7 million in 2025, then dropped by 2.71% to $471.5 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $471.5 million in Q1 2026, $484.7 million in Q4 2025, and $511.6 million in Q3 2025.